Bar Pharmaceuticals S.r.l.

This early-phase study tests the safety and tolerability of a new drug called BAR502 in 52 healthy adults aged 18-55. Participants receive either a single or multiple doses of BAR502 or a placebo. The goal is to see how the body handles the drug and check for side effects before …